medigraphic.com
ISSN 1561-3070 (Electronic)

2019, Number 4

<< Back Next >>

Rev Cub Oftal 2019; 32 (4)

Clinical-pathological characteristics and management of orbital lymphoma

Abreu PFA, Saborit MY, Ortiz RDL, Jiménez GJJ, Nazario DM

Language: Spanish
References: 22
Page:
PDF size: 279.73 Kb.


ABSTRACT

Objective: To identify the clinical-pathological characteristics of orbital lymphoma, as well as the management modalities used and the outcomes achieved.
Methods: A descriptive, retrospective case series study was carried out at the Institute of Oncology and Radiobiology. The sample consisted of 42 patients with diagnosis of orbital ymphoma, and was characterized according to age, sex, clinical presentation, laterality, anatomical location, histopathological diagnosis, clinical stage, treatment received, and status in the last control.
Results: 52.4% of the sample studied was female and 61.9% were older than 60 years. 45.2% of the cases were diagnosed with non-Hodgkin lymphoma in the marginal zone similar to a lymphoid tumor associated with mucous membranes; and 66.7%, with primary orbital clinical presentation. 50% of the lesions affected the tissues of the orbital cavity and unilaterally in 88.3%. 66.7% were classified in stage I, and T2 85.7% were classified as T2. 45.2% received the combination of chemotherapy and radiotherapy treatment. Complete remission was achieved in 88.3%.
Conclusions: The lymphoma of the marginal zone similar to lymphoid tumor associated with mucous membranes is a Non-Hodgkin lymphoma that predominates in the orbit, in patients over 60 years of age and with a discrete female predominance. The purely orbital (primary) clinical presentation is more frequent; and within the cavity, the tissues of the latter are more affected. Most cases are classified in stages I and T2. The combined chemotherapy and radiotherapy treatment is the most applied.


REFERENCES

  1. Li EY, Yuen HK, Cheuk W. Lymphoproliferative disease of the orbit. Asia Pac J Ophthalmol (Phila) 2015;4:106-11.

  2. Abreu FA, Ortiz DL, Santos D, González JL, Fernández O, Caballero Y. Características clínicas y patológicas de los tumores orbitarios. Rev Cubana Oftalmol. 2018;31(2):1-12.

  3. Murrieta H, Villalobos A, García SE. Linfoma: aspectos clínicos y de imagen. México: Rev An Radiol. 2009;1:81-97.

  4. Okoli TC, Peer CJ, Dunleavy K, Figg WD. Targeted PI3Kd inhibition by the small molecule idelalisib as a novel therapy in indolent non-Hodgkin lymphoma. Cancer Biol Ther. 2015;16(2):204- 6.

  5. Galnares JA, Farrell L, Cadena JA, Muñoz O. Linfoma orbitario: reporte de un caso y revisión de la literatura. Rev Mex Oftalmol. 2014;88:141-5.

  6. Gómez Y, García D, Trujillo L. Supervivencia de los pacientes con linfoma no Hodgkin difuso B de células grandes. Acta Méd Cent. 2017;11(3):2-12.

  7. Hindsø TG, Esmaeli B, Holm F, et al. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma. Br J Ophthalmol. 2019;0:1-6.

  8. Verdijk RM. Lymphoproliferative tumors of the ocular adnexa. Asia Pac J Ophthalmol. 2017;6:132- 42.

  9. Di Nisio LA, Zárate J, Weil D. Linfomas orbitarios. Oftalmol Clin Exp. 2017;10(3):88-93.

  10. Pizarro ME, Corredor S, Salcedo G, Rodríguez A. Linfoma orbitario: reporte de un caso. Rev Mex Oftalmol. 2006;80(2):89-92.

  11. Romero MB, Hernández MM, Durán MA. Linfoma B difuso de células grandes. Características patológicas y de inmunofenotipo en 148 pacientes estudiados en el Hospital General de México. Rev Mex Hosp Gen Mex. 2006;69:192-8.

  12. Caballero R, Hernández EG, López JX. Experiencia de 10 años en linfomas oculares y de anexos oculares. Gac Med Mex. 2006;142(5):393-7.

  13. Cahill M, Moriarty P, Barnes C, Kennedy S. Ocular adnexal lymphoma–comparison of MALT lymphoma with other histologlcal types. Br J Ophthalmol. 1999;83:742–7.

  14. Cabrera C, Santana J, Rodríguez D, Olivera O, Miranda MA. Linfoma no Hodgkin con infiltración ocular: a propósito de un caso. Rev Arch Med Camagüe 2016;20(2):212-8.

  15. Kirkegaard MM, Coupland SE, Prause JU, Heegaard S. Malignant lymphoma of the conjunctiva. Surv Ophthalmol. 2015;60(5):444-58.

  16. Kiesewetter B. Clinical features, treatment and outcome of mucosa-associated lymphoid tissue (MALT) lymphoma of the ocular adnexa: single center experience of 60 patients. PLoS One 2014;9:e104004.

  17. Munch-Petersen HD, Rasmussen PK, Coupland SE, et al. Ocular Adnexal Diffuse Large B-cell Lymphoma. A Multicenter International Study. Jama Ophthalmol. 2014;133(2):165-73.

  18. Romero MB, Tenorio G, Guevara S. Linfomas de órbita y anexos oculares: características clínicas e histopatológicas. Rev Med Hosp Gen Mex. 2010;73(3):166-72.

  19. Gadegaard T, Holm F, Hjorth L, et al. Orbital lymphoma-an international multicenter retrospective study. Elsevier. 2019;199:44-57.

  20. Díaz CM, Rodríguez O, MC, Vázquez E, Alsina S. Linfomas no Hodgkin de localización orbitaria. Instituto Nacional de Oncología y Radiobiología. Rev Cubana Oncol. 2000;2(16):79-87.

  21. Seresirikachorn K, Norasetthada L, Ausayakhun S, et al. Clinical presentation and treatment outcomes of primary ocular adnexal MALT lymphoma in Thailand. Blood Res. 2018;53(4):307-13.

  22. Coupland SE, Krause L, Delecluse HJ, et al. Lymphoproliferative Lesions of the Ocular Adnexa. Analysis of 112 Cases. Ophthalmology. 1998;105:1430-41.




2020     |     www.medigraphic.com